Farrell Tyson, MD
Ophthalmology · Cape Coral, FLNPI 1508857491
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $495,728 of the $578,739 with a category attached, or 85.7%. 29 manufacturers reported payments, led by Carl Zeiss Meditec Cataract Technology Inc. at 51.0% of the total. Reporting peaked in 2021 at $133,902 and has fallen 80.1% since, to $26,690 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 493 payments — averaging $1173.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec Cataract Technology Inc.$295K
- Alcon$146K
- Rxsight Inc$38K
- Bausch & Lomb Americas Inc.$35K
- Alcon Research LLC$21K
- Carl Zeiss Meditec, Inc.$19K
- plus $24K from 23 others
Across 143 payments — averaging $2430.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Carl Zeiss Meditec Cataract Technology Inc.$172K
- Glaukos Corporation$84K
- Carl Zeiss Meditec Production LLC$39K
- Alcon Research LLC$24K
- AbbVie$17K
- Bausch Health US, LLC$9K
- plus $3K from 1 others
What the payments were for
- Consulting fees$495,72886%
- Speaking & faculty fees$22,3064%
- Travel & lodging$38,8127%
- Food & beverage$16,4473%
- Education$5,4461%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec Cataract Technology Inc. | 85 | $295,204 |
| Alcon | 145 | $146,444 |
| Rxsight Inc | 7 | $37,972 |
| Bausch & Lomb Americas Inc. | 54 | $35,070 |
| Alcon Research LLC | 9 | $21,300 |
| Carl Zeiss Meditec, Inc. | 16 | $18,615 |
| Carl Zeiss Meditec USA, Inc. | 10 | $9,997 |
| Carl Zeiss Meditec AG | 1 | $6,000 |
| Johnson & Johnson Surgical Vision, Inc. | 31 | $1,428 |
| Dutch Ophthalmic Research Center (international) B.v. | 5 | $1,340 |
| AbbVie(2 entities) | 38 | $1,171 |
| Glaukos Corporation | 21 | $963 |
| Lensar, Inc. | 9 | $667 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $531 |
| Dutch Ophthalmic, USA | 9 | $526 |
| Sun Pharmaceutical Industries Inc. | 6 | $315 |
| Aerie Pharmaceuticals, Inc. | 4 | $240 |
| Ivantis, Inc | 6 | $217 |
| Harrow Eye, LLC | 2 | $173 |
| Dompe US, Inc. | 3 | $159 |
| Bausch Health US, LLC | 1 | $102 |
| Carl Zeiss Meditec Production LLC | 1 | $69 |
| Rayner Intraocular Lenses Limited | 4 | $65 |
| Kala Pharmaceuticals, Inc. | 3 | $53 |
| Eyepoint US, Inc. | 1 | $43 |
| Novartis | 1 | $28 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Lombart Brothers, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$56,219
- MiCor$55,575
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$37,762
- NGENUITY$26,453
- AcrySof IQ PanOptix$25,274
- AcrySof IQ PanOptix UV IOL$23,032
- enVista MX60 IOL$17,507
- miLOOP$17,369
- AcrySof$13,876
- None Specified$13,000
- IC-8 Apthera IOL$12,897
- STELLARIS ELITE$9,747
- QUATERA 700$9,520
- CALLISTO eye$9,340
- ENVISTA ENVY IOL$9,199
- Crystalens Accommodating IOL (AT-52AO)$9,199
- PanOptix$8,795
- VERACITY SURGICAL$7,980
- AcrySof IQ VIVITY$7,246
- IOLMaster 700$6,680
How this compares
$578,739 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 13 | $12,201 |
| TobradexTobramycin/Dexamethasone | 13 | $4,322 |
| Timolol Maleate | 64 | $2,350 |
| Latanoprost | 160 | $1,900 |
| Brimonidine Tartrate | 12 | $370 |
| Dorzolamide Hcl | 13 | $253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $1,171 | $12,20113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Cape Coral
- John StephensCape Coral$226K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.